Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors versus glinides
2017-004406-18Phase 4Terminated
- Sponsor
- INRCA
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by INRCA. Primary endpoint: Change in inflammation markers at 24 weeks. Started Apr 2020; status: terminated.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-004406-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004406-18.